Clinical trials
Early Breast Cancer clinical trials
Below are recruiting early breast cancer clinical trials, each written for real people, not researchers. We’re tracking 430 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06380751RecruitingPhase 3
New targeted therapy for BRCA/PALB2-mutated HR+ breast cancer
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
Gilbert, ArizonaAges 18 years+ - NCT06048835Recruiting
Studying tumor cells in breast cancer patients
This trial looks at tumor cells in the blood of women with breast cancer to understand them better. It may help doctors learn more about how the disease spreads.
Pavia, LombardyAges 18–90 - NCT05914961Recruiting
Tracking inflammation response in triple-negative breast cancer
This trial studies how a blood inflammation marker (CRP) changes after starting immunotherapy plus chemotherapy in people with triple-negative breast cancer. Results may help doctors predict who benefits from treatment and when.
TübingenAges 18 years+ - NCT05798338Recruiting
Study blood samples and tiny cell particles in breast cancer
This study looks at tiny particles released by cells (called extracellular vesicles) in people with breast cancer. It may help researchers better understand breast cancer and how it behaves, which could improve future testing or treatments.
Pavia, LombardyAges 18–90 - NCT05404321Recruiting
Collecting tumor samples to study triple-negative breast cancer treatments
This study collects tumor tissue from people with early-stage triple-negative breast cancer before they start neoadjuvant chemotherapy. The goal is to help researchers test new therapies and look for markers that may predict who benefits.
CaenAges 18 years+ - NCT01000883Recruiting
Biopsy study linking breast cancer tissue markers to treatment response
This study looks at breast cancer samples taken by biopsy to see how tissue “molecular markers” relate to how you respond to therapy and how the cancer behaves. It may help researchers better match future treatments to the biology of your tumor.
Chapel Hill, North CarolinaAges 18 years+ - NCT07242352RecruitingPhase 3
Comparing elacestrant to standard hormone therapy for high-risk early breast cancer
This trial tests a new hormone therapy drug called elacestrant against standard hormone treatments for people with a specific type of early breast cancer (ER+/HER2-) that has a high chance of coming back. The goal is to see if elacestrant works better at keeping the cancer from returning.
Mannheim, Baden-WurttembergAges 18 years+ - NCT06492759RecruitingPhase 2
High-dose radiation with pembrolizumab and chemo for pd-l1 positive tnbc
This trial tests giving high-dose radiation along with the immunotherapy drug pembrolizumab and chemo to people with a specific subtype of advanced breast cancer (PD-L1 positive triple negative). It may help shrink tumors and keep them from growing.
Atlanta, GeorgiaAges 18 years+ - NCT06358573RecruitingPhase 2
Injecting INT230-6 then immunochemo before surgery for early TNBC
This trial tests a two-step approach: first, an injection of the drug INT230-6 directly into the breast tumor, followed by a combination of immunotherapy and chemotherapy before surgery. The goal is to see if this sequence can shrink or eliminate the cancer more effectively, potentially allowing for a less extensive surgery.
LyonAges 18 years+ - NCT06291896Recruiting
Testing microwave imaging for breast cancer screening
This study tests a new, safe microwave-based device (MammoWave) to screen for breast cancer. It compares the device's results with standard mammograms to see if it can find cancer early in women at average risk.
Genova, GenovaAges 45–74 - NCT05792150Recruiting
Registry for young women with certain early breast cancer treatments
This registry collects information from pre- or perimenopausal women with early breast cancer who are treated with standard care, plus tumor testing like MammaPrint®. It may help doctors better understand which treatments work best for different risk groups.
Baden-Baden, Baden-WurttembergAges 18–60 - NCT04468061RecruitingPhase 2
Study chemo drug plus immunotherapy for metastatic triple-negative breast cancer
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
Stamford, ConnecticutAges 18 years+ - NCT05062707Recruiting
Study of early aging in young people during cancer treatment
This study looks at how “early aging” changes show up during treatment in young adults with cancer. It may help doctors better understand health effects during curative therapy and improve care for people your age.
GroningenAges 18–39 - NCT04254263RecruitingPhase 3
Pyrotinib after breast cancer therapy for HER2-positive early disease
This trial studies whether adding pyrotinib after standard treatment helps prevent breast cancer from coming back in people with HER2-positive early-stage breast cancer. You may be eligible if you finished chemotherapy plus trastuzumab and still had signs of cancer in the tissue removed during surgery.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06279364RecruitingPhase 3
Testing SKB264 vs standard chemo for advanced triple-negative breast cancer
This trial tests a new drug called SKB264 against standard chemotherapy options for people with advanced triple-negative breast cancer who have not yet received chemotherapy for their advanced disease. The goal is to see if SKB264 works better than the usual treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT03417115Recruiting
Breast cancer registry study of treatment and outcomes
This is a registry study that collects real-world information about breast cancer care at the start of treatment. It may help researchers better understand which treatments work best for different groups of people.
Many LocationsAges 18 years+ - NCT01788839Recruiting
Long-term health and fertility study for women with breast cancer
This study follows women with breast cancer and certain lymphomas to understand long-term sexual and reproductive health. It may help researchers better support patients’ body changes and wellness over time during and after treatment.
Basking Ridge, New JerseyAges 18 years+ - NCT07743190RecruitingPhase 2
Lighter chemo for early-stage triple-negative breast cancer with high immune cells
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
Syracuse, New YorkAges 18 years+ - NCT03784651Recruiting
How breast cancer treatment changes metabolism and bone
This study looks at how standard breast cancer treatments affect your body’s metabolism and bones in postmenopausal people with early-stage breast cancer. It may help doctors better predict and prevent bone and metabolic side effects from treatment.
Copenhagen, DanmarkAges 50–70 - NCT07372079RecruitingPhase 2
Immunotherapy and chemotherapy before surgery for early triple-negative breast cancer
This trial tests a new immunotherapy combination with chemotherapy given before breast cancer surgery, to shrink the tumor and improve outcomes. It's for people with early-stage triple-negative breast cancer whose tumors are larger than 2 cm.
TianjinAges 18–75 - NCT05323409Recruiting
Better overall care for certain cancer patients
This study looks at how to improve day-to-day support and coordination between cancer doctors and primary care doctors for people with certain early cancers. It may help if you have other ongoing health problems (like diabetes or high blood pressure) or lifestyle factors that need ongoing management during cancer treatment.
Houston, TexasAges 18 years+ - NCT07216495Recruiting
Exercise study for early-stage triple-negative breast cancer patients
This study tests if aerobic exercise can help women and men with stage 2 or 3 triple-negative breast cancer who are getting chemotherapy and immunotherapy before surgery. It aims to see if exercise improves treatment outcomes and quality of life.
Houston, TexasAges 18 years+ - NCT04481763RecruitingPhase 1/Phase 2
Camrelizumab plus radiation for early triple-negative breast cancer
This trial studies whether adding camrelizumab (an immunotherapy drug) to radiation can improve outcomes and be safe for people with early triple-negative breast cancer. It is designed for specific early-stage cases after breast surgery, using tumor and blood tests to match the cancer’s features.
Nanchang, JiangxiAges 18–75 - NCT05447702RecruitingPhase 2
Testes pre-surgery treatment for triple-negative breast cancer
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
Chengdu, SichuanAges 18–75
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for early breast cancer?
- Yes. Clin2 currently lists 430 recruiting early breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a early breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a early breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.